SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Meta Expands AI Training With Employee Activity Tracking Tools 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
NEW YORK, May 23, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics") (NYSEMKT:IMUC) securities between May 1, 2012 and December 11, 2013.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/immunocellular-therapeutics-ltd?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; (2) as a result of this scheme, the market was led to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well and the Company's share price was artificially inflated.
On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that had engaged in stock promotion schemes.
If you suffered a loss in ImmunoCellular Therapeutics you have until June 30, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/immunocellular-therapeutics-ltd?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
